DPP4 and malignant mesothelioma: Notably, the humanized anti-CD26 mAb, YS110, which recognizes the cell membrane-proximal glycosylated region starting at the 20-amino acid flexible stalk region of human CD26, has demonstrated meaningful antitumor effects in malignant mesothelioma models [4].